BNL:  Departments  |  Science  |  ESS&H  |  Newsroom  |  Administration  |  Visitors  |  Directory

search

Office Contact Info.
Phone: (631) 344-3604
Fax: (631) 344-2358
Mail address: Bldg. 490

Leonard Mausner

Scientist


Telephone:  (631) 344-4457
e-mail:  mausner@bnl.gov

Research Interests

  • Development of high specific activity radionuclides for nuclear oncology
  • Techniques for the production of yttrium-86 for tumor imaging with PET prior to administration of Yttrium-90 labeled antibody for therapy and copper-67, scandium-47, and mercury-195m for tumor therapy with somatostatin-type receptor binding peptide and with angiogenic peptides.

 Education & Concurrent Positions

  • B.S. Massachusetts Institute of Technology, 1968.
  • M.A. Princeton University, 1972.
  • Ph.D. Princeton University, 1975.
  • Assistant Scientist, Argonne National Laboratory, 1977-1981.
  • Associate Scientist, Medical Department, BNL, 1981-1983.
  • Head, Brookhaven Linac Isotope Producer (BLIP) and isotope production/distribution program, BNL, 1983-present.
  • Scientist, BNL. 1983-2003.
  • Senior Scientist, BNL. 2003-present.

Selected Publications

  • Mausner L.F. and Mirzadeh S.  Reactor Production of Radionuclides, in: Handbook of Radiopharmaceuticals: Radiochemistry and Applications, M.J. Welch and C.Redvanly eds. John Wiley & Sons Ltd., NY (2003).
  • Kolsky K.L., Meinken G.E.,Kurczak S., Mausner L.F. and Srivastava S.C.  Production of high specific activity Ge-68 at Brookhaven National Laboratory. J. Radioanalytical and Nuclear Chemistry, 2005; 263:553-557.
  • DeNardo S.J., DeNardo G.L., Kukis D.L., Shen S., Kroger L.A., DeNardo D.A., Goldstein D.S., Mirick G.R., Salsko Q., Mausner L.F., Srivastava S.C. and Meares C.F.  Cu-67-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity, tumor regressio in patients with lymphoma. J. Nuclear Medicine, 1999; 40(2):302-310.
    • PubMed
  • Kolsky K.L., Joshi V., Mausner L.F., Srivastava S.C.  Radiochemical purification of no-carrier-added scandium-47 for radioimmunotherapy. Int. J. Applied Radiation and Isotopes, 1998; 49(12):1541-1549.
    • PubMed
  • Mausner L.F., Kolsky K.L., Joshi V. and Srivastava S.C.  Radionuclide development at BNL for nuclear medicine therapy. Int. J. Applied Radiation and Isotopes, 1998; 49(4):285-294.
    • PubMed
  • Srivastava S.C., Atkins H.L., Krishnamurthy G.T., Zanzi I., Silberstein G., Mainken G., Mausner L.F., Swailem F., D’Alessandro T., Cabahug C.J., Lau Y., Park T. and Madajewicz S.  Treatment of metastatic bone pain with Tin-117m stanic diethylenetriaminepentaacetic acid: A phase I/II clinical study. Clinical Cancer Research, 1998;4(1):61-68.
    • PubMed

Top of Page

Last Modified: March 7, 2008
Please forward all questions about this site to: Denise Monteleone
 


DOE, Office of ScienceOne of ten national laboratories overseen and primarily funded by the Office of Science of the U.S. Department of Energy (DOE), Brookhaven National Laboratory conducts research in the physical, biomedical, and environmental sciences, as well as in energy technologies and national security. Brookhaven Lab also builds and operates major scientific facilities available to university, industry and government researchers. Brookhaven is operated and managed for DOE’s Office of Science by Brookhaven Science Associates, a limited-liability company founded by Stony Brook University, the largest academic user of Laboratory facilities, and Battelle, a nonprofit, applied science and technology organization.

Privacy and Security Notice  | Contact Web Services for help